FDA Approves Updated COVID Shots for High-Risk Groups: What the Protocol Says
The Food and Drug Administration on Thursday approved updated coronavirus vaccines for high-risk populations, including adults 65 and older and individuals with underlying health conditions. The authorization covers new mRNA formulations from Pfizer-BioNTech and Moderna, plus a protein-based shot from Sanofi. Distribution is expected within days, but federal recommendation protocols remain in legal limbo.
What does the FDA's latest approval cover?
The FDA authorized updated vaccines for adults 65 and over, as well as those with at least one condition elevating severe-disease risk. The qualifying conditions mirror last year's list: diabetes, obesity, chronic kidney disease, physical inactivity, and similar parameters.
Pediatric authorization varies by platform. Moderna's vaccine applies to ages 6 months and older. Pfizer's covers ages 5 and up. Sanofi's non-mRNA formulation is cleared for ages 12 and older.
This approval continues the narrower framework established last year, when the FDA shifted from universal access to targeted authorization for high-risk cohorts. That policy, initiated by former FDA Commissioner Marty Makary and former regulator Vinay Prasad, requires randomized controlled trials before approval for healthy individuals aged 6 months to 64 years.
Off-label administration remains available. Clinicians can prescribe the vaccine to populations outside FDA approval, weighing medical society guidance, federal recommendations, and individual patient data.
Who is the vaccine officially recommended for?
The recommendation layer is unresolved. The Advisory Committee on Immunization Practices (ACIP), which typically votes annually on vaccine guidance, has not scheduled a meeting. A federal judge in March blocked most of the Trump administration's vaccine policy changes, including the appointment of Secretary Robert F. Kennedy Jr.'s selected members, several of whom had publicly criticized mRNA vaccines.
Two Kennedy-era modifications remain active: no recommendation for pregnant women, and a shared-decision-making framework for healthy children. The broader universal recommendation remains suspended by court order.
Jennifer Kates, senior vice president at KFF, described the situation as unprecedented.